

Checklist of the ENCePP Code of Conduct

The purpose of this checklist is to emphasize the key elements of the ENCePP Code of Conduct that are relevant at the time of study start. The act of completing this checklist confirms that the study complies – at the time of submission - with the core principles of the Code.

The checklist must be completed¹ by the (primary) lead investigator of the study who should:

- Tick all boxes of each section thereby confirming compliance of the study with the Code's core principles and respective provisions for implementation. In case of sub-sections (e.g. 2.A. and 2.B.), tick all boxes of the sub-section that applies to the study.
- If applicable, provide additional information as requested.
- Sign the checklist.

The undersigned declares upon honour the following answers on behalf of the organisation that he/she represents. Signature should be by the (primary) lead investigator.

1. General	Check
The study has been designed in line with the Code's core principles of • scientific independence (see Chapter 3.1 of the Code), and • transparency (see Chapter 3.2 of the Code).	☒ ☒
2. Research contract	Check
2.A. Studies financed purely from one's own general resources (100% self-funded)	
A declaration on the use of one's own general resources, making clear references to the study and the (primary) lead investigator and being signed by (an) authorised representative(s) of the participating study entity/ies is available.	☐
2.B. Studies receiving financing from external sources	
A research contract between the (primary) lead investigator and/or the coordinating study entity and the study funder has been concluded prior to study start.	☒
The contract includes the following information:	

¹ Complete the Checklist on screen, then print and scan a signed and stamped (if applicable) copy.

The latest version of the full study protocol is uploaded to the EU PAS Register ⁵ .	☒
A system is in place to allow for documentation of changes to the original version of the study protocol in a traceable and auditable way.	☒
Information on all parties involved in the writing and adoption of the protocol including a brief description of their contribution is being made publicly available.	☒
A detailed statistical analysis plan is described and included in or annexed to the study protocol.	☒
5. Intellectual property rights and sharing of data	Check
A system has been put in place in order to record the data collected and processed in the study in a way that allows corroboration of published results.	☒
A detailed description of how raw data were transformed into the data set for analysis will be available at the end of the study.	☒
All possible steps to provide for audits by competent authorities will be taken.	☒
Appropriate plans and agreements, if necessary, are being or have been made to respond to requests for data sharing in line with the <i>Implementation Guidance on Sharing of Study Data</i> (Annex 4).	☒
A procedure for access to the analytical data is described in, or annexed to, the study protocol including the degree to which data can be shared and, if access is restricted, a justification why access is limited. Please indicate the page number in the study protocol: 19	☒
6. Declaration of interest	Check
Declarations of interests of the core team members involved in the conduct of the study are documented and be made public (including members of the study steering group or committee, if established).	☒
All persons with a financial, commercial or institutional interest in a particular outcome of the study are excluded from participation in any study activity which could influence the results or interpretation thereof in a particular direction.	☒

⁵ When uploading the protocol in the EU PAS Register[®], it may not be immediately accessible to the public unless the (primary) lead investigator so chooses.

7. Study steering group or committee	Check
7.A. Absence of a study steering group or committee	
Please check here if no steering group or committee is foreseen for the study.	☒
7.B. Establishment of study steering group or committee is foreseen	
No expert with a direct conflict of interest is appointed as a member.	☐
The composition is being/will be made publicly available.	☐
8. Publication/Reporting of studies	Check
Appropriate plans and agreements, if necessary, have been made (e.g. as part of the dissemination and communication policy) ensuring publication of results - including results from prematurely terminated studies. - independent of statistical significance and whether the results are positive or negative. - in form of a clear summary of the main results. - in form of an abstract uploaded to the EU PAS Register[®] within 3 months after the final study report. (Note that requests for delays are possible pending response to peer-review comments). - in form of a full report of all results with a scientific or public health impact without delay (taking into account relevant legal provisions in case of a suspected public health impact). - independently by the (primary) lead investigator irrespective of data ownership. - providing for the possibility of review by the study funder prior to submission – but without unjustified delay. - considering comments from the study funder and enabling the study funder to request changes to the presentation of the results to delete confidential information. - making publicly available comments of the funder. - taking into account the provisions for authorship of the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by the International Committee of Medical Journal Editors (ICMJE).	☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒

9. Confidential information

Check

A definition of what constitutes confidential information has been agreed between the parties of the research contract.



The definition of confidential information does not consider data and results as being confidential except in relation to relevant data privacy laws.




Name of the coordinating study entity: PhaseIVCPH

Name of (primary) lead investigator: Janne Petersen

Date: 27 April 2020

Signature:



Stamp (if applicable)